Eisai Company, Limited

Esai Co., Ltd.

Manabu Murakami

Isao Yamatsu

Kiyoshi Oketani

Shinya Abe

Takeshi Suzuki

Katsuya Tagami

Hideaki Fujisaki

Naoyuki Shimomura

Toshihiko Kaneko

Shigeru Souda

Shuhei Miyazawa

Norihiro Ueda

Seiichiro Nomoto

Seiichi Kobayashi

Hisashi Shibata

Makoto Okita

Akiharu Kajiwara

Kouji Nakamoto

Masatoshi Fujimoto

Takashi Inoue

Tsuneo Wakabayashi

Yuichi Inai

Kouji Yamada

Kouichi Katayama

Hajime Tsunoda

Hideki Ono

Shigeki Hibi

Yasushi Okamoto

Tetsuya Kawahara

Takashi Yamanaka

Osamu Asano

Hitoshi Harada

Masanobu Shinoda

Nobuyuki Yasuda

Junsaku Nagaoka

Naoki Kobayashi

Tatsuo Horizoe

Seiji Yoshikawa

Kouzi Yamada

Hirotoshi Numata

Yoshinori Katoh

Kensaku Kinoshita

Mannen Mishima

Yorihisa Hoshino

Toshiharu Ohgoh

Kaya Ohashi

Shigeto Negi

Shizumasa Kijima

Kenji Hayashi

Nobuhisa Watanabe

Tsutomu Kawata

Toshihiko Naito

Toshikazu Shimizu

Isao Tanaka

Naoki Ozeki

Hiroe Minami

Toyokazu Haga

Hiroshi Akamatsu

Kaya Nagata

Isao Yamatsa

The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonist action. A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof has an adenosine A2 receptor antagonistic action and is useful for prevention or therapy of diabetes mellitus and diabetic complications. In addition, adenosine A2 receptor antagonists having different structures from those of the compounds described above, for example KW6002, are also effective for prevention or therapy of diabetes mellitus and diabetic complications. In the formula, W is &#x2014;CHCH&#x2014;, or &#x2014;CH&#x2550;CH&#x2014; or &#x2014;C&#x2261;C&#x2014;; Ris:(in the formula, X is hydrogen atom, hydroxyl group, a lower alkyl group, a lower alkoxy group, etc.; and Rand Rare the same as or different from each other and each represents hydrogen atom, a lower alkyl group, a cycloalkyl group, etc.) and the like; Ris an amino group, etc. which maybe substituted with a lower alkyl group, etc.; Ris a cycloalkyl group, an optionally substituted aryl group, etc.; and Ris a lower alkyl group etc.

Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes

The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action. That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I);(wherein Rrepresents e.g. an amino group which may be substituted with an alkyl group; Rrepresents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; Rrepresents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.

Condensed imidazole compounds and a therapeutic agent for diabetes mellitus

Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are described.

Pyridine derivatives having anti-ulcerative activity

Pyridine derivatives useful for preventing or treating peptic ulcers, pharmaceutical preparations and methods of treating peptic ulcers are disclosed.

A pyridine compound having the formula is disclosed and useful to treat the peptic ulcer. ##STR1## wherein R.sup.1 and R.sup.2 which may be the same or different are each a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogenated lower alkyl group, or a halogen atom, R.sup.3 and R.sup.4 which may be the same or different are each a hydrogen atom or a lower alkyl group, X is a group represented by the formula --S--, a group represented by the formula ##STR2## or a group represented by the formula ##STR3## and n is an integer of 1 to 6, provided that R.sup.3 and R.sup.4 are not simultaneously hydrogen atoms when n is 1.

Pyridine derivative and therapeutic agent for ulcer comprising the same

A benzothiazole derivative or a pharmacologically acceptable salt thereof of the following formula, as defined in the claims, which is useful as a preventive or therapeutic agent for diseases on which functions of suppressing leukotrienes and thromboxanes production are effective: ##STR1##

Benzothiazole compounds which are substituted by pyridymethyl

A benzothiazole derivative or a pharmacologically acceptable salt thereof which is useful as a preventive or therapeutic agent for diseases on which functions of suppressing leukotrienes and thromboxanes production are effective. A benzothiazole derivative represented by the following general formula (I): ##STR1##

Pyridyl substituted benzothiazole compounds which have useful

A benzothiazole derivative or a pharmacologically acceptable salt thereof which is useful as a preventive or therapeutic agent for diseases on which functions of suppressing leukotrienes and thromboxanes production are effective. A benzothiazole derivative represented by the following general formula (I): ##STR1## wherein R.sup.1 and R.sup.3 are either the same or different and represents a hydrogen atom, a lower alkyl group or a lower alkoxy group; R.sup.4 represents a group represented by the formula --(CH.sub.x)--.sub.q wherein q is a integer of from 1 to 4;

A pyridinium salt is useful as an antiulcer and is defined by the following formula. It includes a sulphenamide compound and a pyridinium compound. J is benzoimidazole, K is --S-- or --SSR, Z is hydroxy or oxyalkyl. ##STR1##

Pyridinium salt and pharmacological composition containing the same

A novel polyprenyl compound is identified with the formula and useful for a pharmaceutical drag. ##STR1## wherein X represents a group of the formula: ##STR2## (wherein R.sup.1 and R.sup.2, which may be the same or different, represent each a hydrogen atom, a lower alkyl group, a hydroxyalkyl group, or a lower alkenyl group); a group of the formula: ##STR3## (wherein A including the nitrogen atom shown represents a ring containing nitrogen and oxygen atoms); or a group of the formula: ##STR4## (wherein R.sup.3 represents a hydrogen atom or a lower alkyl group, and R.sup.4 represents a lower alkyl group); Y represents a group of the formula: ##STR5## or a group of the formula: ##STR6## (wherein R.sup.5 represents a hydrogen atom or a lower alkyl group), and n represents an integer of from 2 to 5.

Polyprenyl compound and pharmaceutical use

Dolichol or phosphate thereof is useful as a therapeutically treating and preventive agent, in particular, for hyperuricuria, hyperlipemia, diabetes and hepatic diseases.

Therapeutic and preventive agent containing dolichol

A novel polyprenyl compound is identified with the formula and useful for a pharmaceutical drag. ##STR1## wherein X represents a group of the formula: ##STR2## (wherein R.sup.1 and R.sup.2, which may be the same or differnt, represent each a hydrogen atom, a lower alkyl group, a hydroxyalkyl group, or a lower alkenyl group); a group of the formula: ##STR3## (wherein A including the nitrogen atom shown represents a ring containing nitrogen and oxygen atoms); or a group of the formula: ##STR4## (wherein R.sup.3 represents a hydrogen atom or a lower alkyl group, and R.sup.4 represents a lower alkyl group); Y represents a group of the formula: ##STR5## or a group of the formula: ##STR6## (wherein R.sup.5 represents a hydrogen atom or a lower alkyl group), and n represents an integer of from 2 to 5.

Growing community of inventors

Ibaraki, Japan

Manabu Murakami